Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
All entries for: Stoke Therapeutics, Inc.
March 16, 2026
Stoke Therapeutics, Inc.
Neutral Outlook
Bedford, MA
201-500 employees
In addition, in May 2025, the administration published an executive order regarding most favored nation (“MFN”) drug pricing, which is sometimes referred to as international reference pricing. This executive order directs the Secretary of HHS to communicate MFN price targets to pharmaceutical manufacturers, and if significant progress towards MFN pricing is not delivered, to propose a rulemaking plan to implement MFN pricing. Recently, on December 23, 2025, CMS issued proposed regulations to establish, under the Center for Medicare and Medicaid Innovation, two mandatory MFN demonstration models under Medicare Parts B and D, respectively. If these rules or other MFN pricing rules are finalized, they are likely to mandate reduced prices of at least some drugs in the United States, if they are also sold in comparator countries.
November 4, 2025
Stoke Therapeutics, Inc.
Neutral Outlook
Bedford, MA
201-500 employees
Healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (“IRA”) in August 2022, which, among other things, allows U.S. Department of Health and Human Services (“HHS”) to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that the Centers for Medicare & Medicaid Services (“CMS”) reimburses under Medicare Part B and Part D.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic